Long term responders to palliative chemotherapy for advanced biliary tract cancer.
Authors
Doherty, MMcNamara, Mairéad G
Aneja, P
McInerney, E
Moignard, S
Horgan, A
Jiang, H
Panzarella, T
Jang, R
Dhani, N
Hedley, D
Knox, J
Affiliation
Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, CanadaIssue Date
2017-04
Metadata
Show full item recordAbstract
Patients with advanced biliary tract cancer (BTC) are often treated with palliative chemotherapy (PC). Standard PC since 2010 is a cisplatin/gemcitabine doublet, with median overall survival (OS) of 11.7 months from the ABC-02 trial. Prior to this, our institutional standard was gemcitabine and fluoropyrimidine. The ABC-02 study used 8 cycles of PC as standard with treatment stopped even in the absence of disease progression, but some patients may benefit from continuing PC longer than 8 cycles.Citation
Long term responders to palliative chemotherapy for advanced biliary tract cancer. 2017, 8 (2):352-360 J Gastrointest OncolJournal
Journal of Gastrointestinal OncologyDOI
10.21037/jgo.2017.03.06PubMed ID
28480074Type
ArticleLanguage
enISSN
2078-6891ae974a485f413a2113503eed53cd6c53
10.21037/jgo.2017.03.06